These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 7212408)

  • 1. Activated coagulation time in monitoring heparinized dogs.
    Green RA
    Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
    Greene CE; Meriwether E
    Am J Vet Res; 1982 Aug; 43(8):1473-7. PubMed ID: 7103231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
    Hellebrekers LJ; Slappendel RJ; van den Brom WE
    Am J Vet Res; 1985 Jul; 46(7):1460-2. PubMed ID: 4026027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
    Wilkerson RD; Conran PB; Greene SL
    Lab Anim Sci; 1984 Feb; 34(1):62-5. PubMed ID: 6716959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
    Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
    Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [-Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty-].
    Kunert M; Sorgenicht R; Scheuble L; Ketteler T; Lürken E; Meyer I; Müller A; Emmerich K; Gülker H
    Z Kardiol; 1996 Feb; 85(2):118-24. PubMed ID: 8650981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of the red blood cell mass of horses: toxic effect of heparin anticoagulant therapy.
    Duncan SG; Meyers KM; Reed SM
    Am J Vet Res; 1983 Dec; 44(12):2271-6. PubMed ID: 6660615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs.
    Diquélou A; Barbaste C; Gabaig AM; Trumel C; Abella-Bourges N; Guelfi JF; Bousquet Mélou A
    Vet Clin Pathol; 2005 Sep; 34(3):237-42. PubMed ID: 16134071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
    Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty.
    Varah N; Smith J; Baugh RF
    Heart Lung; 1990 May; 19(3):265-70. PubMed ID: 2341265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in anticoagulation in dogs assayed by three methods.
    Harrison HN; Gutterman B; Haynie M; Weintraub H; Brandt B
    Lab Anim Sci; 1976 Dec; 26(6 Pt 1):917-21. PubMed ID: 1018478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated coagulation and activated partial thromboplastin times in assessment and reversal of heparin-induced anticoagulation for cardiopulmonary bypass.
    Dauchot PJ; Berzina-Moettus L; Rabinovitch A; Ankeney JL
    Anesth Analg; 1983 Aug; 62(8):710-9. PubMed ID: 6869857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1989 Jun; 61(3):357-62. PubMed ID: 2552604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma heparin values and hemostasis in equids after subcutaneous administration of low-dose calcium heparin.
    Gerhards H; Eberhardt C
    Am J Vet Res; 1988 Jan; 49(1):13-8. PubMed ID: 3354959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sonoclot® evaluation of single- and multiple-dose subcutaneous unfractionated heparin therapy in healthy adult dogs.
    Babski DM; Brainard BM; Ralph AG; Pittman JR; Koenig A
    J Vet Intern Med; 2012; 26(3):631-8. PubMed ID: 22435404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.